Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: PLK1
Name: polo like kinase 1
Location: 16p12.2
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT01437007 TKM 080301 for Primary or Secondary Liver Cancer View
NCT02875002 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas View
NCT04752696 Onvansertib in Combination With Nanoliposomal Irinotecan Leucovorin and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma View
NCT00536835 Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma View
NCT01262235 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors NET and Adrenocortical Carcinoma ACC Patients View
NCT01348347 BI 6727 Volasertib Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours View
NCT05358379 A Study to Investigate CYC140 in Subjects With Advanced Solid Tumors and Lymphoma View
NCT03303339 Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia AML View
NCT05450965 Study of PLK1 Inhibitor Onvansertib in Relapsed Small Cell Lung Cancer View
NCT03414034 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer View
NCT03829410 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation View
NCT05549661 Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia View
NCT06398587 Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma View